GLP-1 Market
LLY $1150.99 ▼ -1.6% NVO $38.17 ▼ -3.1% PFE $28.18 ▲ +0.9% VKTX $41.65 ▲ +2.0% KLRA $13.13 ▲ +2.7% GPCR $35.95 ▼ -2.6% RHHBY $55.06 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MK-4082 Formulation 2

MK-4082 Formulation 2

Company
Merck Sharp & Dohme LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026

Trial details
  • Active, not recruiting NCT NCT07748351

    A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

    Not yet reported Merck Sharp & Dohme LLC 48 participants Est. completion 2026-12-15 2 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: MK-4082 Formulation 2, MK-4082 Formulation 2 (F2)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.